TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Polynovo ( (AU:PNV) ) just unveiled an announcement.
PolyNovo Limited has requested a trading halt on its securities pending the release of an announcement related to a clinical trial. The trial investigates the effectiveness of NovoSorb BTM combined with negative pressure wound therapy compared to standard care in treating neuroischemic diabetic wounds. This announcement could have significant implications for PolyNovo’s market positioning and stakeholder interests, as it pertains to the potential efficacy of their product in a critical area of wound care.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
More about Polynovo
PolyNovo Limited operates in the medical technology industry, focusing on developing and commercializing innovative wound care solutions. Their primary product, NovoSorb BTM, is used in the treatment of complex wounds, and the company is known for its emphasis on improving patient outcomes.
Average Trading Volume: 2,677,259
Technical Sentiment Signal: Sell
Current Market Cap: A$967.2M
For an in-depth examination of PNV stock, go to TipRanks’ Overview page.